<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11117DED-1FA6-4714-A680-FB438063C627"><gtr:id>11117DED-1FA6-4714-A680-FB438063C627</gtr:id><gtr:name>Multimedica Research Hospital Milan</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at South Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/23D04EC2-3A05-4711-B472-F29894825709"><gtr:id>23D04EC2-3A05-4711-B472-F29894825709</gtr:id><gtr:name>Institute of Zoology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11117DED-1FA6-4714-A680-FB438063C627"><gtr:id>11117DED-1FA6-4714-A680-FB438063C627</gtr:id><gtr:name>Multimedica Research Hospital Milan</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D1F308D7-56DC-4AFA-AE5C-8DED24D9C168"><gtr:id>D1F308D7-56DC-4AFA-AE5C-8DED24D9C168</gtr:id><gtr:firstName>Nicolle</gtr:firstName><gtr:surname>Kraenkel</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5ACB5C11-9B05-4384-A43B-BB35454ACDA9"><gtr:id>5ACB5C11-9B05-4384-A43B-BB35454ACDA9</gtr:id><gtr:firstName>Costanza</gtr:firstName><gtr:surname>Emanueli</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CCC6148D-71B4-4741-A4E7-437334125DA6"><gtr:id>CCC6148D-71B4-4741-A4E7-437334125DA6</gtr:id><gtr:firstName>Paolo</gtr:firstName><gtr:surname>Madeddu</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900912"><gtr:id>FFC97323-520A-42D1-B71E-38146C691DFA</gtr:id><gtr:title>Function-based Enrichment of Pro-angiogenic Cells for Cardiac Repair</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900912</gtr:grantReference><gtr:abstractText>Heart disease is the most common course for death and illness across Europe. Standard therapy can rescue and preserve heart function only to a certain degree, still leaving the patient with a poor quality of life. Initial studies have tested the potential of injecting the patient s own bone marrow stem cells into the damaged heart muscle. We therefore know that the treatment is safe and can improve heart function more than classical therapy alone. However, researchers believe that the cells which are injected should be characterised and selected better to make sure they perform their supposed function.
In the proposed study, we want to select for cells which are able to actively travel towards a substance involved in attraction of regenerative stem cells. We have demonstrated before that this method can be used to isolate cells which have certain characteristics necessary for their beneficial action. However, the better function of the selected cells needs to be demonstrated in a mouse model mirroring the situation of the human patient. 
Once we have shown that cells selected on the basis of their functional ability perform better than currently used cells, we will be in the position to develop a clinically applicable method improving the efficiency of stem cell therapy.</gtr:abstractText><gtr:technicalSummary>Coronary heart disease remains the number 1 killer in developed countries. Regenerative medicine aims to repair the ischaemic heart, an objective not achieved with current interventions. Recent clinical trials have demonstrated the feasibility and safety of autologous bone marrow cell transplantation. However, the therapeutic potential remains below its potential. A main obstacle being the reduced regenerative potential of progenitor cells from patients with cardiovascular diseases. We recently developed a separation strategy based on a functional parameter ? migration towards a chemoattractant - whereby we have been able to enrich for pro-angiogenic progenitor cells. Moreover, using the same technique, we could obtain a cell population of equal in vitro potency from patients with acute myocardial infarction as from healthy controls. We now aim to validate and optimize the isolation procedure and verify the therapeutic potential of cells separated by migration in an animal model of myocardial infarction against two cell currently used populations. We expect that migration-enriched cells are superior to the two control cell populations currently in clinical use (total bone marrow cells and CD34+ progenitor cells) in their ability to induce re-vascularization in the infarcted myocardium, preserve a number and function of cardiomyocytes, and minimize scarring and inflammation. If validation satisfies expected outcomes, we will be in the position to develop a clinically applicable method improving the efficiency of stem cell therapy.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>299594</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Multimedica Research Hospital Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Discovery of the role of kallikrein system in migratory capacity of human proangiogenic cells</gtr:description><gtr:id>7A6AE212-32A3-4B91-962B-9EE77702C68B</gtr:id><gtr:impact>publication</gtr:impact><gtr:outcomeId>Kik5TrpNqgC-1</gtr:outcomeId><gtr:partnerContribution>coauthorship in a publication</gtr:partnerContribution><gtr:piContribution>senior autorship in publication</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Cardiovascular Center</gtr:department><gtr:description>Methodological development of adhesion assay</gtr:description><gtr:id>40F47E51-854E-4D12-9FB2-7BCC71AE5D9B</gtr:id><gtr:impact>publication</gtr:impact><gtr:outcomeId>mZq2zAWUgNx-1</gtr:outcomeId><gtr:partnerContribution>Coauthorship</gtr:partnerContribution><gtr:piContribution>Develop a further method to enrich cell based on adhesion properties</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The assay allows for separation of functionally competent cells from human bone marrow</gtr:description><gtr:id>E6F4FDA5-6CCC-4DE8-8AD5-28B392927557</gtr:id><gtr:impact>future potential application for cell therapy</gtr:impact><gtr:outcomeId>tQFAuf7WoCw</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>migration assay to select functional stem cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8AC22236-04AF-47C4-9833-BA8B7CEF437B</gtr:id><gtr:title>Migratory activity of circulating progenitor cells and serum SDF-1a predict adverse events in patients with myocardial infarction.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce22b54fb1a2724815038e5ee5b9fc60"><gtr:id>ce22b54fb1a2724815038e5ee5b9fc60</gtr:id><gtr:otherNames>Fortunato O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>pm_13315_25_23761401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12E2A102-4D17-4C19-B278-801BE28FBC2B</gtr:id><gtr:title>Migratory activity of circulating mononuclear cells is associated with cardiovascular mortality in type 2 diabetic patients with critical limb ischemia.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b460ed8087bde2d707925d775a1675"><gtr:id>e8b460ed8087bde2d707925d775a1675</gtr:id><gtr:otherNames>Spinetti G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>545cc84753b0c8.83902292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A13329C-25A7-47AC-A6EF-0261264899AD</gtr:id><gtr:title>A novel flow cytometry-based assay to study leukocyte-endothelial cell interactions in vitro.</gtr:title><gtr:parentPublicationTitle>Cytometry. Part A : the journal of the International Society for Analytical Cytology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21534e9f70e6869871d31735feaa44b9"><gtr:id>21534e9f70e6869871d31735feaa44b9</gtr:id><gtr:otherNames>Kr?nkel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1552-4922</gtr:issn><gtr:outcomeId>TsqJUYVTfeu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3161DC84-7457-4EFA-860F-2E0B313D47BC</gtr:id><gtr:title>Close encounters of the third kind: progenitor cells land on the platelet-enriched vascular surface.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b460ed8087bde2d707925d775a1675"><gtr:id>e8b460ed8087bde2d707925d775a1675</gtr:id><gtr:otherNames>Spinetti G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>LTB93oVnbGh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B284B8E-6D3C-407A-B6E4-04969C9D77A8</gtr:id><gtr:title>Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21534e9f70e6869871d31735feaa44b9"><gtr:id>21534e9f70e6869871d31735feaa44b9</gtr:id><gtr:otherNames>Kr?nkel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13315_25_23275384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AF042C4-54EF-4B8E-B703-8BE07E3DB965</gtr:id><gtr:title>Migration towards SDF-1 selects angiogenin-expressing bone marrow monocytes endowed with cardiac reparative activity in patients with previous myocardial infarction.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03fd2d531b40dc66017626a38de20887"><gtr:id>03fd2d531b40dc66017626a38de20887</gtr:id><gtr:otherNames>Ascione R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>5675e2b8c439d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A454D493-ADC9-401F-96FA-7BD9B50FD99D</gtr:id><gtr:title>The role of chemokines, cytokines and adhesion molecules in stem cell trafficking and homing.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0104f5eff142ccc0a3d38fde990ef71"><gtr:id>b0104f5eff142ccc0a3d38fde990ef71</gtr:id><gtr:otherNames>Cui Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>a9ffknMh2Uv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6198C310-9260-4537-BCBF-3F3C00147951</gtr:id><gtr:title>Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8b460ed8087bde2d707925d775a1675"><gtr:id>e8b460ed8087bde2d707925d775a1675</gtr:id><gtr:otherNames>Spinetti G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>gVTKBnuWdkF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900912</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>